Roche Holding AG (RHHBY)
| Previous close | 35.58 |
| Open | 35.92 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 35.92 - 36.20 |
| 52-week range | 31.77 - 41.71 |
| Volume | |
| Avg. volume | 2,104,309 |
| Market cap | 233.319B |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | 18.46 |
| EPS (TTM) | 1.95 |
| Earnings date | N/A |
| Forward dividend & yield | 1.28 (3.55%) |
| Ex-dividend date | 16 Mar 2023 |
| 1y target est | 40.40 |
GlobeNewswireRoche's Kadcyla is the first targeted therapy to show significant overall survival benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treatment
Phase III KATHERINE results reinforce Kadcyla as the standard of care for this population, with more than 82,000 people treated to date1,2Long-term data also showed continued benefit in invasive disease-free survival for adjuvant Kadcyla compared to Herceptin in this study2These data will be presented as an oral presentation at the 2023 San Antonio Breast Cancer Symposium and included in the official press programme Basel, 8 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today posi
- GlobeNewswire
Roche’s inavolisib combination reduces the risk of disease progression by 57% in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
Inavolisib in combination with palbociclib and fulvestrant more than doubled progression-free survival compared to palbociclib and fulvestrant alone1The inavolisib combination has the potential to address resistance to treatment and poor prognosis associated with PIK3CA mutations2-5 These new data are being presented today in an oral presentation at the 2023 San Antonio Breast Cancer Symposium and shared with health authorities Basel, 8 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presente
Business WireGenentech’s Inavolisib Combination Reduces the Risk of Disease Progression by 57% in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
SOUTH SAN FRANCISCO, Calif., December 08, 2023--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today positive results from the Phase III INAVO120 study evaluating inavolisib in combination with palbociclib (Ibrance®) and fulvestrant as a first-line treatment for people with PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative, endocrine-resistant, locally advanced or metastatic breast cancer.
